In Brief: Merck Aggrastat
Merck Aggrastat: FDA's Cardiovascular & Renal Drugs Advisory Committee will discuss NDAs 20-912 and 20-913 for Merck's tirofiban April 10. The applications cover two indications: use in combination with heparin for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events and use in patients with coronary ischemic syndromes undergoing percutaneous translumenal coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth